Bronze
Aptamer Sciences Inc., a spin-out biotech company from POSTECH in 2011, hasfocused on commercializing cutting-edge aptamer technologies in broad applicationsof research tools, diagnosis and therapeutics.Aptamer Sciences‘ proprietary aptamer technology platform using modifiednucleotides affords attractive protein binders with better specificity andbinding affinity. Aptamer Sciences has developed global partnerships with universities,hospitals and industry players and also several in-house programs. Key pipelineproducts in diagnostics include IVDs for lung cancer, pancreatic cancer etc. AptoDetect™-Lungfor early detection of lung cancer has been approved by MFDS (formerly KFDA) in2017 and is preparing its launching. Fortherapeutics, novel mode of action anti-diabetic aptamers is going to enterinto pre-clinical development stage and several anti-cancer compounds has beendiscovered and optimized.
AptoDetect™-Lung is intended to be used as an in vitro assay for the detection of a panel of seven proteins, C9, CA6, EGFR1, MMP7, SERPINA3, KIT, and CRP, in human serum to aid in the early detection of lung cancer in high risk patients and risk stratification of patients with indeterminate nodules identified by CT.